HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1- (6- chloro- 3- pyridylmethyl)- 7- methyl- 8- nitro- 1,2,3,5,6,7- hexahydroimidazo(1,2- a)pyridin- 5- ol

an insecticide; structure in first source

Also Known As:

IPP 10; IPP-10; IPP10 cpd

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - 1-(6-chloro-3-pyridylmethyl)-7-methyl-8-nitro-1,2,3,5,6,7-hexahydroimidazo(1,2-a)pyridin-5-ol: 2
- Bridged-Ring Heterocyclic Compounds
  - Heterocyclic Bridged Bicyclo Compounds
    - Azabicyclo Compounds
      - 1-(6-chloro-3-pyridylmethyl)-7-methyl-8-nitro-1,2,3,5,6,7-hexahydroimidazo(1,2-a)pyridin-5-ol: 2
Organic Chemicals: 133
- Aza Compounds: 3
  - Azabicyclo Compounds
    - 1-(6-chloro-3-pyridylmethyl)-7-methyl-8-nitro-1,2,3,5,6,7-hexahydroimidazo(1,2-a)pyridin-5-ol: 2

Experts

1.	Cai, Hai: 1 article (02/2019)
2.	Chen, Shao-Hao: 1 article (02/2019)
3.	Chen, Shao-Zhan: 1 article (02/2019)
4.	Li, Xiao-Dong: 1 article (02/2019)
5.	Lin, Ting-Ting: 1 article (02/2019)
6.	Wei, Yong: 1 article (02/2019)
7.	Wu, Yu-Peng: 1 article (02/2019)
8.	Xu, Ning: 1 article (02/2019)
9.	Xue, Xue-Yi: 1 article (02/2019)
10.	Zheng, Qing-Shui: 1 article (02/2019)

Related Diseases

1.	Urinary Retention 12/01/2017 - "Patients with IPP>10 mm should be counseled regarding the high chance of need for surgical treatment following acute urinary retention."
2.	Neoplasms (Cancer) 02/01/2019 - "Univariate analysis indicated that the factors influencing the recovery of urinary continence included IPP, body mass index (BMI), bladder neck preservation (BNP), neurovascular bundle preservation (NVBP) and clinical tumor (T) stage at 3 months (P < 0.05 or P < 0.01), age, IPP, BMI, BNP and clinical T stage at 6 months (P < 0.05 or P < 0.01), and age, IPP, BMI, BNP, NVBP and clinical T stage at 12 months (P < 0.05), while multivariate logistic regression analysis showed the independent influencing factors to be IPP > 10 mm (P < 0.001), BMI ≥ 25 kg/m2 (P = 0.004) and BNP (P = 0.032) at 3 months, and IPP and BMI at 6 months (both P < 0.01) and 12 months (P < 0.01 and P = 0.033). "

Related Drugs and Biologics

1.	indolepropanol phosphate (IPP)